United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $7.27, $0.18 better than the analyst estimate of $7.09. Revenue for the quarter came in at $783.3 million versus the consensus estimate of $807.05 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.